FIELD: pharmaceuticals.
SUBSTANCE: group of inventions relates to the field of medicine, namely, to a hypoglycemic pharmaceutical combination containing: (a) a glucokinase activator, constituting a compound represented by the following formula:
HMS5552,
or a pharmaceutically acceptable salt thereof; and (b) an SGLT-2 inhibitor selected from empagliflozin, dapagliflozin, and canagliflozin, also relates to a hypoglycemic pharmaceutical composition containing the hypoglycemic pharmaceutical combination, also relates to a hypoglycemic combined composition with a fixed dosage, containing: (a) a glucokinase activator, which is a compound represented by the following formula:
HMS5552,
or a pharmaceutically acceptable salt thereof; (b) an SGLT-2 inhibitor selected from empagliflozin, dapagliflozin, and canagliflozin; and (c) one or multiple excipients, also relates to a method for preventing, inhibiting progression of, delaying, or treating one or multiple metabolic disorders selected from the group consisting of type I diabetes, type II diabetes, glucose tolerance disorder, disorder of fasting blood glucose, hyperglycemia, hyperglycemia after eating, excessive weight, obesity, hypertension, insulin resistance, diabetic nephropathy, reduced renal function and/or metabolic syndrome; or improving control of the blood glucose level and/or reducing the level of fasting plasma glucose, plasma glucose after a meal, and/or of glycosylated hemoglobin HbA1c; or preventing, inhibiting, delaying or regressing complications associated with diabetes, including administering a therapeutically effective amount of the hypoglycemic pharmaceutical combination, or hypoglycemic pharmaceutical composition, or combined formulation with a fixed dosage to the subject, and also relates to an application of the hypoglycemic pharmaceutical combination, or hypoglycemic pharmaceutical composition, or hypoglycemic combined formulation with a fixed dosage in production of a medicinal product for preventing, inhibiting progression of, delaying, or treating one or multiple metabolic disorders selected from the group consisting of type I diabetes, type II diabetes, glucose tolerance disorder, fasting blood glucose disorder, hyperglycemia, hyperglycemia after eating, excessive weight, obesity, hypertension, insulin resistance, diabetic nephropathy, reduced renal function, and/or metabolic syndrome; or improving control of the blood glucose level and/or reducing the level of fasting plasma glucose, plasma glucose after a meal, and/or glycosylated hemoglobin HbA1c.
EFFECT: group of inventions provides an excellent hypoglycemic effect resulting from combining HMS5552 and an SGLT-2 inhibitor.
122 cl, 2 dwg, 12 tbl, 30 ex
